Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Cash (2016 - 2025)

Historic Change in Cash for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$4.2 million.

  • Protalix BioTherapeutics' Change in Cash fell 20593.52% to -$4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$13.8 million, marking a year-over-year decrease of 29657.19%. This contributed to the annual value of -$3.9 million for FY2024, which is 15938.99% down from last year.
  • Protalix BioTherapeutics' Change in Cash amounted to -$4.2 million in Q3 2025, which was down 20593.52% from -$1.6 million recorded in Q2 2025.
  • Protalix BioTherapeutics' Change in Cash's 5-year high stood at $28.3 million during Q4 2021, with a 5-year trough of -$27.8 million in Q3 2023.
  • Its 5-year average for Change in Cash is -$243052.6, with a median of -$302000.0 in 2025.
  • Its Change in Cash has fluctuated over the past 5 years, first surged by 49896.45% in 2021, then plummeted by 151194.89% in 2022.
  • Protalix BioTherapeutics' Change in Cash (Quarter) stood at $28.3 million in 2021, then tumbled by 77.45% to $6.4 million in 2022, then tumbled by 49.52% to $3.2 million in 2023, then crashed by 337.1% to -$7.6 million in 2024, then skyrocketed by 44.46% to -$4.2 million in 2025.
  • Its Change in Cash was -$4.2 million in Q3 2025, compared to -$1.6 million in Q2 2025 and -$302000.0 in Q1 2025.